SLC5A2 and type 2 diabetes mellitus: Despite emerging trials, there are limitations in systematically assessing the efficacy and safety of SGLT2 inhibitors among patients hospitalized with AHF, therefore, our objective is to address the current knowledge gap surrounding the effectiveness of SGLT2 inhibitors compared with placebo in patients with or without type 2 diabetes.